Manidipina Doc Generici (Manidipine Dihydrochloride)

Manidipine acts on the cardiovascular system to manage elevated blood pressure in the following condition:

• Hypertension: reduction of elevated arterial blood pressure in adult patients.

• Manidipine dihydrochloride selectively inhibits L‑type calcium channels on vascular smooth muscle cells, decreasing calcium influx. This leads to relaxation of arterial smooth muscle, vasodilation, and a consequent fall in peripheral vascular resistance, which lowers systemic arterial pressure in patients with hypertension.

Manidipine may cause a range of adverse reactions. Monitoring for any new symptoms is recommended.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: sensation of warmth and redness, usually temporary.
• Peripheral edema: swelling of ankles or feet, may be dose‑related.
• Dizziness: especially upon standing quickly.
• Nausea: mild gastrointestinal upset.
• Tachycardia: increased heart rate in some individuals.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure leading to fainting.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Angioedema: swelling of face, lips, tongue, potentially airway‑compromising.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Cardiac arrhythmias: irregular heart rhythms requiring medical attention.
• Renal impairment: sudden decrease in kidney function.

Before initiating therapy, certain precautions should be observed.

• Monitor blood pressure: check regularly to assess therapeutic response.
• Assess renal function: adjust use if significant impairment is present.
• Evaluate hepatic status: use with caution in patients with liver disease.
• Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension.
• Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
• Store at room temperature: keep in the original container, protect from moisture and light.

Manidipine may interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Concomitant use with other potent antihypertensives (e.g., ACE inhibitors, ARBs): risk of excessive hypotension.
• Grapefruit juice: can elevate drug exposure and precipitate hypotension.

Moderate Interactions (Monitor Closely)

• Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): additive cardiac effects.
• Diuretics: may enhance blood pressure lowering and affect electrolyte balance.
• Beta‑blockers: monitor heart rate and blood pressure for additive effects.